Susquehanna International Group
XENE icon

Susquehanna International Group’s Xenon Pharmaceuticals XENE Stock Holding History

Susquehanna International Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.2M Buy
467,000
+387,200
+485% +$17.8M ﹤0.01% 1863
2025
Q4 		$3.58M Buy
79,800
+50,000
+168% +$2.1M ﹤0.01% 4576
2025
Q3 		$1.2M Sell
29,800
-49,800
-63% -$1.75M ﹤0.01% 6929
2025
Q2 		$2.49M Sell
79,600
-62,700
-44% -$2.05M ﹤0.01% 5337
2025
Q1 		$4.77M Buy
142,300
+70,900
+99% +$2.69M ﹤0.01% 3739
2024
Q4 		$2.8M Buy
71,400
+63,400
+793% +$2.62M ﹤0.01% 4602
2024
Q3 		$315K Sell
8,000
-2,700
-25% -$109K ﹤0.01% 9494
2024
Q2 		$417K Buy
+10,700
New +$428K ﹤0.01% 8713
2024
Q1 		– Sell
-20,400
Closed -$940K – 13496
2023
Q4 		$940K Sell
20,400
-15,400
-43% -$544K ﹤0.01% 7131
2023
Q3 		$1.22M Buy
35,800
+3,500
+11% +$131K ﹤0.01% 6184
2023
Q2 		$1.24M Buy
32,300
+17,800
+123% +$708K ﹤0.01% 6195
2023
Q1 		$519K Buy
14,500
+7,400
+104% +$273K ﹤0.01% 8469
2022
Q4 		$280K Sell
7,100
-26,300
-79% -$958K ﹤0.01% 9260
2022
Q3 		$1.21M Buy
33,400
+23,500
+237% +$845K ﹤0.01% 6153
2022
Q2 		$301K Sell
9,900
-3,300
-25% -$99.8K ﹤0.01% 9558
2022
Q1 		$404K Sell
13,200
-53,700
-80% -$1.61M ﹤0.01% 9523
2021
Q4 		$2.09M Sell
66,900
-86,500
-56% -$2.58M ﹤0.01% 5399
2021
Q3 		$2.34M Buy
+153,400
New +$2.67M ﹤0.01% 5509

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group's XENE Position: Q1 2026 in Review

Susquehanna International Group increased its Xenon Pharmaceuticals (XENE) stake by 2,029% in Q1 2026, buying an estimated $7.78M and bringing the position to 177,137 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3070.

Susquehanna International Group first reported a position in XENE in Q2 2017 and has held it in 15 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Susquehanna International Group held 177,137 shares of Xenon Pharmaceuticals worth $10.3M as of Q1 2026.
  • Susquehanna International Group bought 168,818 Xenon Pharmaceuticals shares in Q1 2026, an estimated $7.78M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3070 holding.
  • Susquehanna International Group first reported a position in Xenon Pharmaceuticals in Q2 2017 and has held it in 15 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.